For engagement of the cancer cells, we exploit folate receptor alpha (FRα) that is over-expressed on ~40% of human cancers (53) and induce cancer cell engagement with the CAR T cells by injection of a folate-fluorescein (folate-FL) bispecific adapter. Here, FOLR1 is linked to cancer.